Alain Mita, MD
Medical Oncology · San Antonio, TXNPI 1285602565
Payments from drug & device makers
Across 235 payments — averaging $10,509 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Co., Ltd.$578K
- Biontech SE$446K
- Pfizer$409K
- Merck$349K
- EMD Serono, Inc.$255K
- Janssen Research & Development, LLC$96K
- plus $336K from 22 others
What the payments were for
- Consulting fees$4,17049%
- Speaking & faculty fees$6808%
- Travel & lodging$1,83522%
- Food & beverage$1,66420%
- Education$1312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | 28 | $577,806 |
| Biontech SE | 74 | $446,249 |
| Pfizer | 27 | $409,491 |
| Merck | 7 | $349,073 |
| EMD Serono, Inc. | 20 | $254,750 |
| Janssen Research & Development, LLC | 7 | $95,923 |
| Taiho Oncology, Inc. | 12 | $53,395 |
| Amgen | 6 | $45,190 |
| Gilead | 6 | $43,651 |
| E.r. Squibb & Sons, L.L.C. | 8 | $39,887 |
| Astrazeneca UK Limited | 2 | $38,717 |
| Genentech, Inc. | 5 | $38,679 |
| Coherus Oncology, Inc. | 6 | $34,482 |
| GSK | 11 | $31,300 |
| Beone Medicines Ltd. | 1 | $5,552 |
| Beigene, Ltd. | 1 | $3,701 |
| Life Technologies Corporation | 1 | $496 |
| Sanofi | 1 | $350 |
| Daiichi Sankyo Inc. | 3 | $273 |
| Theratechnologies Inc. | 1 | $120 |
| Mirati Therapeutics, Inc. | 1 | $109 |
| Seagen Inc. | 1 | $104 |
| Tempus AI, Inc | 1 | $45 |
| Legend Biotech USA Inc. | 1 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,469,507 in reported general payments places this provider in the 80th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 14 | $357,489 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $138,997 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $779 |
| Ondansetron Hcl | 36 | $464 |
| Dexamethasone | 22 | $407 |
| Prochlorperazine Maleate | 38 | $296 |
| Olanzapine | 19 | $229 |
| Omeprazole | 16 | $99 |
| Prednisone | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in San Antonio
- Amita PatnaikSan Antonio$17.8M
- Anthony TolcherSan Antonio$15.9M
- Sukeshi AroraSan Antonio$9.1M
- John SarantopoulosSan Antonio$9M
- Virginia KaklamaniSan Antonio$5.5M
- Lei ZhengSan Antonio$5.3M
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.